KRAS and colorectal cancer: Although details on treatment alterations were not available from the survey, two of the four cases are colorectal cancers harboring well-known activating mutations in KRAS (p.G13D) and BRAF (p.V600E) and we suspect that the patients decided not to pursue cetuximab/panitumumab treatment and may have enrolled in clinical trials on MEK inhibitors.